Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Penpulimab in Second-line Small Cell Lung Cancer
NCT05001971Phase 2Completed
- Sponsor
- Hunan Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, penpulimab in small cell lung cancer (SCLC), sponsored by Hunan Cancer Hospital. Started Jan 2021; status: completed.
02
Drugs
anlotinibpenpulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05001971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001971.